Quantum-Si Announces the Appointment of Industry Veteran Johan Denecke as Senior Vice President of Operations
21 Junho 2023 - 9:00AM
Business Wire
Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or
the “Company”), The Protein Sequencing Company™, today announced
the appointment of Johan Denecke as Senior Vice President of
Operations, effective June 20, 2023. Mr. Denecke will be
responsible for scaling up production and driving operational and
quality excellence in support of the commercialization of
Quantum-Si’s next-generation, single-molecule protein sequencing
platform.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20230621345723/en/
(Photo: Business Wire)
Mr. Denecke brings more than 20 years of experience as a
cross-functional operations executive in engineering, quality
assurance and best-in-class manufacturing practices. Having held
executive positions in both private and public sectors, including
at Illumina as Vice President of Manufacturing Engineering, and
Thermo Fisher Scientific as Vice President of Quality Assurance, he
brings a wealth of experience to the table. Most recently, he
served as Senior Vice President of Operations at Atomica where he
scaled the organization yielding significant growth, efficiency,
and waste reduction.
“Mr. Denecke has a proven track record of leading high-growth,
cross-functional teams that have delivered products with quality,
speed and cost efficiency,” said Dr. Patrick Schneider, President
and Chief Operating Officer of Quantum-Si. “His expertise across
multiple aspects of global operations and integrated supply chain
strategically positions Quantum-Si for growth as it continues its
mission to solve complex biological problems through accessible
protein sequencing.”
“With a passion for driving operations excellence, I am honored
to serve as a senior member of Quantum-Si’s executive team as we
work to optimize our supply chain and increase operational
efficiency to drive higher gross margins. I look forward to
leveraging my expertise to help the company achieve its strategic
goals and deliver innovative solutions to our customers,” said Mr.
Denecke.
Mr. Denecke holds a Bachelor of Science and Master of Science in
aerospace engineering from the Massachusetts Institute of
Technology.
Michael McKenna, Ph.D., whose service and leadership were
integral to the Company’s product development and pre-revenue
stage, will transition out of his role as Executive Vice President
of Product Development and Operations at Quantum-Si at the end of
July 2023.
About Quantum-Si Incorporated
Quantum-Si, The Protein Sequencing CompanyTM, is focused on
revolutionizing the growing field of proteomics. The Company's
suite of technologies is powered by a first-of-its-kind
semiconductor chip designed to enable next-generation
single-molecule protein sequencing and digitize proteomic research
in order to advance drug discovery and diagnostics beyond what has
been possible with DNA sequencing. Learn more at
www.quantum-si.com.
Forward Looking Statements
This press release includes "forward-looking statements" within
the meaning of the "safe harbor" provisions of the United States
Private Securities Litigation Reform Act of 1995. The actual
results of the Company may differ from its expectations, estimates,
and projections and, consequently, you should not rely on these
forward-looking statements as predictions of future events. Words
such as "expect," "estimate," "project," "budget," "forecast,"
"anticipate," "intend," "plan," "may," "will," "could," "should,"
"believes," "predicts," "potential," "continue," and similar
expressions (or the negative versions of such words or expressions)
are intended to identify such forward-looking statements. These
forward-looking statements include, without limitation, the
Company's expectations with respect to future performance and
development and commercialization of products and services. These
forward-looking statements involve significant risks and
uncertainties that could cause the actual results to differ
materially from those discussed in the forward-looking statements.
Most of these factors are outside the Company's control and are
difficult to predict. Factors that may cause such differences
include, but are not limited to: the impact of COVID-19 on the
Company's business; the inability to maintain the listing of the
Company's Class A common stock on The Nasdaq Stock Market; the
ability to recognize the anticipated benefits of the business
combination, which may be affected by, among other things,
competition and the ability of the Company to grow and manage
growth profitably and retain its key employees; the Company's
ongoing leadership transition; changes in applicable laws or
regulations; the ability of the Company to raise financing in the
future; the success, cost and timing of the Company's product
development and commercialization activities; the commercialization
and adoption of the Company’s existing products and the success of
any product the Company may offer in the future; the potential
attributes and benefits of the Company’s commercialized PlatinumTM
protein sequencing instrument and the Company’s other products once
commercialized; the Company's ability to obtain and maintain
regulatory approval for its products, and any related restrictions
and limitations of any approved product; the Company's ability to
identify, in-license or acquire additional technology; the
Company's ability to maintain its existing lease, license,
manufacture and supply agreements; the Company's ability to compete
with other companies currently marketing or engaged in the
development or commercialization of products and services that
serve customers engaged in proteomic analysis, many of which have
greater financial and marketing resources than the Company; the
size and growth potential of the markets for the Company's products
and services, and its ability to serve those markets once
commercialized, either alone or in partnership with others the
Company's estimates regarding future expenses, future revenue,
capital requirements and needs for additional financing; the
Company's financial performance; and other risks and uncertainties
described under "Risk Factors" in the Company’s Annual Report for
the fiscal year ended December 31, 2022, and in the Company's other
filings with the SEC. The Company cautions that the foregoing list
of factors is not exclusive. The Company cautions readers not to
place undue reliance upon any forward-looking statements, which
speak only as of the date made. The Company does not undertake or
accept any obligation or undertaking to release publicly any
updates or revisions to any forward-looking statements to reflect
any change in its expectations or any change in events, conditions,
or circumstances on which any such statement is based.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230621345723/en/
Investors Juan Avendano ir@quantum-si.com
Media Michael Sullivan msullivan@spectrumscience.com
Quantum Si (NASDAQ:QSI)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Quantum Si (NASDAQ:QSI)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024